The Mucopolysaccharidosis drugs in development market research report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Mucopolysaccharidosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mucopolysaccharidosis and features dormant and discontinued products.
GlobalData tracks 86 drugs in development for Mucopolysaccharidosis by 45 companies/universities/institutes. The top development phase for Mucopolysaccharidosis is preclinical with 44 drugs in that stage. The Mucopolysaccharidosis pipeline has 80 drugs in development by companies and six by universities/ institutes. Some of the companies in the Mucopolysaccharidosis pipeline products market are: JCR Pharmaceuticals, Phoenix Nest and Gain Therapeutics.
The key targets in the Mucopolysaccharidosis pipeline products market include Alpha L-Iduronidase (IDUA or EC 3.2.1.76), Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50), and Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13).
The key mechanisms of action in the Mucopolysaccharidosis pipeline product include Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Activator with ten drugs in Phase II. The Mucopolysaccharidosis pipeline products include 13 routes of administration with the top ROA being Intravenous and 11 key molecule types in the Mucopolysaccharidosis pipeline products market including Gene Therapy, and Recombinant Enzyme.
Mucopolysaccharidosis overview
Mucopolysaccharidosis (MPS) refers to a group of inherited metabolic disorders causing the accumulation of complex sugars in cells, affecting various organs. Classified into different types (I-VII), symptoms vary widely but may include skeletal abnormalities, organ enlargement, developmental delays, and impaired vision or hearing. Diagnosis involves genetic testing and enzyme assays. Treatment focuses on managing symptoms and may involve enzyme replacement therapy, stem cell transplantation, or supportive care. While not curable, therapies aim to improve quality of life. Early detection, multidisciplinary care, and ongoing monitoring help alleviate symptoms and improve outcomes for individuals with mucopolysaccharidosis.
For a complete picture of Mucopolysaccharidosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
